Forte Biosciences reports positive Phase 1b data for FB102 in celiac disease; Phase 2 initiating

Forte Biosciences, Inc.

Composite histological VCIEL endpoint met: FB102 mean change 0.079 vs placebo -1.849 (p=0.0099).
CD3+ IELs declined by 1.5 on FB102 vs increase of 13.3 for placebo (p=0.0035).
Gluten challenge GI symptom events per subject: 4.0 for FB102 vs 6.9 for placebo (42% benefit).
No grade 3+ SAEs in FB102 arm; all TEAEs mild; no dropouts.
Phase 2 celiac trial initiating; topline readout expected in 2026; vitiligo readout H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.